S&P Futures
4,607.00 -47.75 (-1.03%) Dow Futures
35,487.00 -309.00 (-0.86%) Nasdaq Futures
15,348.25 -247.50 (-1.59%) Russell 2000 Futures
2,137.00 -20.70 (-0.96%) Crude Oil
84.84 +1.02 (+1.22%) Gold
1,813.10 -3.40 (-0.19%)
Protalix BioTherapeutics, Inc. (PLX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.8850 |
| Open | 0.8700 |
| Bid | 0.8437 x 4000 |
| Ask | 0.8751 x 3000 |
| Day's Range | 0.8100 - 0.9000 |
| 52 Week Range | 0.7900 - 7.0200 |
| Volume | |
| Avg. Volume | 624,056 |
| Market Cap | 39.17M |
| Beta (5Y Monthly) | 2.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4990 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
Fair Value
Related Research
- Protalix BioTherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/04/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 months agoArgus Research
- PR Newswire
Protalix BioTherapeutics Issues 2021 Letter to Stockholders
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.
- Zacks Small Cap Research
PLX: Third Quarter Update
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 3Q:21 financial and operational results in a November 15, 2021 press release and filing of Form 10-Q . Promulgation of the reports was followed by a pre-market conference call which discussed recent achievements. Operational
- PR Newswire
Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2021 and provided a financial and business update on recent corporate, clinical and regulatory developments.
